^
Association details:
| Biomarker: | CXCL12 expression |
|---|---|
| Cancer: | Peripheral T-cell Lymphoma |
| Drug: | Zarnestra (tipifarnib) (CXCL12 inhibitor, Farnesyl transferase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma
Published date:
11/04/2021
Excerpt:
Fifty-eight patients were efficacy evaluable and had an associated ORR of 39.7% (23/58) with most responses observed in the AITL and PTCL-CXCL12+ cohorts. In the 32 patients with AITL, the ORR was 56.3% (18/32), including 9 complete responses (CR) and 9 partial responses (PR). In the 10 patients with PTCL-CXCL12+, the ORR was 40.0% (4/10), including 1 CR and 3 PR. The median OS for patients with AITL was 32.8 months, and the median OS had not been reached for patients with PTCL-CXCL12+...tipifarnib demonstrated very encouraging efficacy in patients with CXCL12-expressing subtypes of PTCL (AITL and PTCL-CXCL12+)...
DOI:
10.1182/blood-2021-147279
Trial ID:
